Vol. 4 No. 4 (2024)
Reimbursement Recommendations

Drospirenone (Slynd)

decorative image of the issue cover

Published April 4, 2024

Key Messages

  • CADTH recommends that Slynd should be reimbursed by public drug plans for conception control in adolescent and adult women if certain conditions are met.
  • Slynd should be covered for conception control in adolescent and adult women provided that Slynd is listed in a similar way to other oral contraceptive pills currently reimbursed by public drug plans for the prevention of pregnancy.
  • Slynd should only be reimbursed if the cost does not exceed that of other progestin-only pills (POPs) for contraception.